SCHEMBL24310453

SCHEMBL24310453

Cc1ccccc1Oc1nc(N[S+]([O-])c2cnn(C)c2)nc(-c2ccccc2CC(C)C)c1C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310131 0.86 — —
SCHEMBL24310452 0.83 HTR1A (0.38) —
SCHEMBL29566521 0.83 HTR1A (0.38) —
SCHEMBL24309974 0.78 MAP4K1 (0.32) —
SCHEMBL24310068 0.76 EGFR (0.35) —
SCHEMBL24309426 0.72 HTR1A (0.42) —
SCHEMBL24309438 0.71 GABRG2 (0.30) —
SCHEMBL24309503 0.71 KDM5A (0.34) —
SCHEMBL24309785 0.69 MAP4K1 (0.33) —
SCHEMBL24310132 0.69 HTR1A (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback